ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

(2022) François-Clément Bidard et al.   CANCER RESEARCH

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

(2022) Francois-Clement Bidard et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

(2021) Gillian Vandekerkhove et al.   Nature Communications

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms

(2021) Hanna Tukachinsky et al.   CLINICAL CANCER RESEARCH

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

(2021) Yoshinori Kagawa et al.   CLINICAL CANCER RESEARCH

Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients

(2021) Aparna R. Parikh et al.   CLINICAL CANCER RESEARCH

Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden

(2021) Guanhua Zhu et al.   Nature Communications

Genomic profile of advanced breast cancer in circulating tumour DNA

(2021) Belinda Kingston et al.   Nature Communications

Liquid Biopsy: From Discovery to Clinical Application

(2021) Catherine Alix-Panabières et al.   Cancer Discovery

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

(2021) E.A. Klein et al.   ANNALS OF ONCOLOGY

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

(2021) Andrea Sartore-Bianchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor–Naive Advanced ALK-Positive Non–Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

(2021) D. Ross Camidge et al.   Journal of Thoracic Oncology

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

(2021) Thomas Powles et al.   NATURE

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

(2021) David M. Kurtz et al.   NATURE BIOTECHNOLOGY

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

(2021) Dana W. Y. Tsui et al.   Genome Medicine

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

(2021) Vivek Subbiah et al.   Lancet Diabetes & Endocrinology

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

(2021) Erika Martinelli et al.   JAMA Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

(2021) A. Gennari et al.   ANNALS OF ONCOLOGY

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

(2021) Tenna Vesterman Henriksen et al.   CLINICAL CANCER RESEARCH

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

(2021) Christian Rolfo et al.   Journal of Thoracic Oncology

Distinction of lymphoid and myeloid clonal hematopoiesis

(2021) Abhishek Niroula et al.   NATURE MEDICINE

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

(2021) Yoshiaki Nakamura et al.   NATURE MEDICINE

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease

(2021) Everett J. Moding et al.   Cancer Discovery

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

(2020) Aparna R. Parikh et al.   CLINICAL CANCER RESEARCH

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

(2020) Alexander Drilon et al.   NATURE MEDICINE

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

(2020) Philip C. Mack et al.   CANCER

IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.

(2020) Elia Aguado et al.   JOURNAL OF CLINICAL ONCOLOGY

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Integrating genomic features for non-invasive early lung cancer detection

(2020) Jacob J. Chabon et al.   NATURE

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

(2020) Junji Tsurutani et al.   Cancer Discovery

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

(2020) M.C. Liu et al.   ANNALS OF ONCOLOGY

Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis

(2020) Hyo Jung Park et al.   RADIOLOGY

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

(2020) Nicholas C Turner et al.   LANCET ONCOLOGY

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

(2020) Kelly L. Bolton et al.   NATURE GENETICS

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

(2020) Yoshiaki Nakamura et al.   NATURE MEDICINE

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

(2020) Shumei Kato et al.   Nature Communications

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

(2020) Qu Zhang et al.   Cancer Discovery

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

(2020) Javier Pascual et al.   Cancer Discovery

International liquid biopsy standardization alliance white paper

(2020) Dana Connors et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

(2020) Kendal Jensen et al.   JAMA Oncology

Liquid biopsy and minimal residual disease — latest advances and implications for cure

(2019) Klaus Pantel et al.   Nature Reviews Clinical Oncology

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

(2019) Funda Meric-Bernstam et al.   LANCET ONCOLOGY

Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.

(2019) Yoshihito Ohhara et al.   JOURNAL OF CLINICAL ONCOLOGY

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial

(2019) S Hrebien et al.   ANNALS OF ONCOLOGY

Germline-Focused Analysis of Tumour-Only Sequencing: Recommendations from the ESMO Precision Medicine Working Group

(2019) D Mandelker et al.   ANNALS OF ONCOLOGY

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden

(2019) Ryma Benayed et al.   CLINICAL CANCER RESEARCH

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

(2019) Emil Christensen et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-wide cell-free DNA fragmentation in patients with cancer

(2019) Stephen Cristiano et al.   NATURE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues

(2019) Keren Yizhak et al.   SCIENCE

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

(2019) Isaac Garcia-Murillas et al.   JAMA Oncology

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

(2019) N Tarazona et al.   ANNALS OF ONCOLOGY

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows

(2019) Rita Lampignano et al.   CLINICAL CHEMISTRY

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

(2019) Pedram Razavi et al.   NATURE MEDICINE

High-accuracy liquid biopsies

(2019) Beatriz Bellosillo et al.   NATURE MEDICINE

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

(2019) Jeanne Tie et al.   JAMA Oncology

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

(2019) Alexander Drilon et al.   LANCET ONCOLOGY

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies

(2018) Robert L. Bowman et al.   Cell Stem Cell

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

(2018) Oliver A. Zill et al.   CLINICAL CANCER RESEARCH

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

(2018) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

(2018) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection and localization of surgically resectable cancers with a multi-analyte blood test

(2018) Joshua D. Cohen et al.   SCIENCE

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

(2018) Ben O’Leary et al.   Nature Communications

Evaluation of pre-analytical factors affecting plasma DNA analysis

(2018) Havell Markus et al.   Scientific Reports

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

(2018) Jenny H. Lee et al.   JAMA Oncology

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

(2018) Clara Montagut et al.   JAMA Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

(2018) C M Parseghian et al.   ANNALS OF ONCOLOGY

LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC

(2018) C Zhou et al.   ANNALS OF ONCOLOGY

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

(2018) Y Wang et al.   ANNALS OF ONCOLOGY

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced detection of circulating tumor DNA by fragment size analysis

(2018) Florent Mouliere et al.   Science Translational Medicine

Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease

(2018) Joshua Moss et al.   Nature Communications

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

(2018) Markus Mayrhofer et al.   Genome Medicine

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

(2018) Chiara Cremolini et al.   JAMA Oncology

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

(2018) Charu Aggarwal et al.   JAMA Oncology

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

(2018) Johann S. de Bono et al.   CLINICAL CANCER RESEARCH

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Blood-based detection ofRASmutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-basedRAStesting

(2017) Wolff Schmiegel et al.   Molecular Oncology

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct detection of early-stage cancers using circulating tumor DNA

(2017) Jillian Phallen et al.   Science Translational Medicine

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

(2017) Eirini Pectasides et al.   Cancer Discovery

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

(2017) Aadel A. Chaudhuri et al.   Cancer Discovery

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

(2017) John H. Strickler et al.   Cancer Discovery

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer

(2017) Nidal Muhanna et al.   Scientific Reports

Origins, structures, and functions of circulating DNA in oncology

(2016) A. R. Thierry et al.   CANCER AND METASTASIS REVIEWS

Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin

(2016) Matthew W. Snyder et al.   CELL

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes

(2016) Qing Kang et al.   CLINICAL BIOCHEMISTRY

Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches

(2016) Felix C.K. Wong et al.   CLINICAL BIOCHEMISTRY

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA

(2016) Sonya Parpart-Li et al.   CLINICAL CANCER RESEARCH

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

(2016) Martin Reck et al.   Journal of Thoracic Oncology

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

(2016) Andrea Sartore-Bianchi et al.   LANCET ONCOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

(2016) Beth O. Van Emburgh et al.   Nature Communications

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

(2016) Christine A. Parkinson et al.   PLOS MEDICINE

Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1.

(2015) C. Montagut et al.   ANNALS OF ONCOLOGY

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

(2015) J. Tie et al.   ANNALS OF ONCOLOGY

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

(2015) Eleonor Olsson et al.   EMBO Molecular Medicine

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

(2015) Oliver Gautschi et al.   Journal of Thoracic Oncology

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

(2015) Leticia De Mattos-Arruda et al.   Nature Communications

Biomarker validation and testing

(2014) Daniel F. Hayes   Molecular Oncology

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

(2014) Ronald Lebofsky et al.   Molecular Oncology

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

(2014) Aaron M Newman et al.   NATURE MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

(2014) E. C. de Bruin et al.   SCIENCE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

High-Resolution Profiling of Fetal DNA Clearance from Maternal Plasma by Massively Parallel Sequencing

(2013) S. C. Y. Yu et al.   CLINICAL CHEMISTRY

The EGAPP initiative: lessons learned

(2013)   GENETICS IN MEDICINE

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE